---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004557"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:54:52.867086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025

## Summary
- Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.
- Full data from Phase 2 VERONA trial of DURAVYU in DME expected 1Q 2025; interim data showed BCVA gain +8.9 letters and CST improvement.
- Cash and investments ~$370M at Dec 31, 2024; cash runway into 2027 beyond Phase 3 wet AMD topline data expected in 2026.
- Appointed retina specialist Reginald J. Sanders, M.D., FASRS to Board of Directors.
- Opened new 40,000+ sq ft cGMP manufacturing facility in Northbridge, MA to support commercial readiness.

## SEC filing metadata
- accession: 0000950170-25-004557
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025004557/0000950170-25-004557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025004557/eypt-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004557
- JSON: https://secwatch.observer/filing/0000950170-25-004557.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.